<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8019636</article-id><article-id pub-id-type="doi">10.1155/2021/6687589</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antitumor Effect of <italic>Inula viscosa</italic> Extracts on DMBA-Induced Skin Carcinoma Are Mediated by Proteasome Inhibition</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2018-5877</contrib-id><name><surname>El Yaagoubi</surname><given-names>Ouadie Mohamed</given-names></name><email>ouadie.elyaagoubi@gmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0849-0038</contrib-id><name><surname>Lahmadi</surname><given-names>Ayoub</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9317-1631</contrib-id><name><surname>Bouyahya</surname><given-names>Abdelhakim</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4265-0066</contrib-id><name><surname>Filali</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7016-8525</contrib-id><name><surname>Samaki</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3534-2476</contrib-id><name><surname>El Antri</surname><given-names>Said</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5666-0970</contrib-id><name><surname>Aboudkhil</surname><given-names>Souad</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Laboratory of Biochemistry, Environment and Agri-Food (URAC 36), Faculty of Sciences and Techniques-Mohammedia, Hassan II University, Casablanca, Morocco</aff><aff id="I2">
<sup>2</sup>Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco</aff><aff id="I3">
<sup>3</sup>Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco</aff><aff id="I4">
<sup>4</sup>National Institute of Social Action (INAS), Tangier, Morocco</aff><author-notes><fn fn-type="other"><p>Academic Editor: Kosuru Ramoji</p></fn></author-notes><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2021</year></pub-date><volume>2021</volume><elocation-id>6687589</elocation-id><history><date date-type="received"><day>3</day><month>1</month><year>2021</year></date><date date-type="rev-recd"><day>15</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2021 Ouadie Mohamed El Yaagoubi et al.</copyright-statement><copyright-year>2021</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The aim of this work is to evaluate the antitumor effect mediated by the proteasome inhibitors of <italic>Inula viscosa</italic> extracts on skin carcinogenesis. Female Swiss albino mice were divided into five groups depending on the combination of skin cancer-inducing 7,12-dimethylbenz(a)anthracene (DMBA) and extract of <italic>Inula viscosa</italic> treatments. Histology of the affected skin and measurement of proteasome activity were performed to demonstrate the effect of <italic>Inula viscosa</italic> on mice. The identification of the molecules responsible for this inhibitory activity was carried out through the docking studies. The results showed that <italic>Inula viscosa</italic> extracts inhibit the development of papilloma in mice. Therefore, the best chemopreventive action of <italic>Inula viscosa</italic> was observed on mice in which extract treatment was performed before and after the induction of skin carcinogenesis. It was revealed that the ingestion of extracts <italic>Inula viscosa</italic> delays the formation of skin papillomas in animals and simultaneously decreases the size and number of papillomas, which is also reflected on the skin histology of the mice treated. Structure&#x02013;activity relationship information obtained from component of <italic>Inula viscosa</italic> particularly tomentosin, inuviscolide, and isocosticacid demonstrated that distinct bonding modes in <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub> subunits determine its selectivity and potent inhibition for <italic>&#x003b2;</italic><sub>5</sub> subunit.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The ubiquitin&#x02013;proteasome system (UPS) plays a fundamental role in intracellular proteolysis. Furthermore, its central role is the degradation of abnormal proteins. Indeed, it is vital for the regulated degradation of intracellular proteins and is directly involved in the regulation of most biological processes such as cell cycle, apoptosis, muscle differentiation, or immune response [<xref rid="B1" ref-type="bibr">1</xref>]. Recently, proteasome levels have been suggested as a biomarker of various cancer diseases [<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>].</p><p>At the heart of this system is the proteasome, which is an essential protease in eukaryotes. The proteolytic core of this complex called proteasome 20S is shaped like a hollow cylinder containing the catalytic sites in internal cavity. Crystal structure (PDB: 4R3O) shows that the active sites of the 20S proteasome are mainly located on the <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub> subunits, which have caspase-like (C-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) activities, respectively.</p><p>Recent studies on the function of these subunits demonstrated that inhibition of <italic>&#x003b2;</italic><sub>5</sub> subunit could achieve therapeutic effects [<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>]. The proteasome inhibition for anticancer therapy, particularly by natural compounds, has produced distinct and promising outcomes of cancer treatment [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Therefore, the use of medicinal plants is an ancient practice because these plants have generated very encouraging therapeutic results with fewer side effects observed during their use since they are less offensive and less harmful to the body [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. Besides, they are relatively less expensive than modern medicine. Given this explosion in the use of medicinal plants and their beneficial effects, we thought it would be interesting to examine the antitumor effect of <italic>Inula viscosa</italic> on the progression of skin cancer in mice.</p><p>
<italic>Inula viscosa</italic> (L.) Aiton (Compositae) locally called &#x0201c;Magramane&#x0201d; is a perennial herbaceous plant distributed in different regions of the Mediterranean Basin [<xref rid="B13" ref-type="bibr">13</xref>]. Therefore, the plant has been used in traditional medicine for treatment of different diseases, including anti-inflammatory [<xref rid="B14" ref-type="bibr">14</xref>], anthelmintic [<xref rid="B15" ref-type="bibr">15</xref>], antipyretic, antiseptic, and antiphlogistic activities [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. In fact, crude extracts prepared from different parts of <italic>Inula viscosa</italic> demonstrated antioxidant [<xref rid="B18" ref-type="bibr">18</xref>] and cytotoxic activities on large variety of cancerous cells [<xref rid="B17" ref-type="bibr">17</xref>]. The present study is aimed at investigating the antitumor promoting effect and proteasome inhibitors of <italic>Inula viscosa</italic> extract in a specific model of DMBA/croton oil-induced skin carcinoma in mice. Indeed, the study of structure&#x02013;activity relationships of bioactive molecules of <italic>Inula viscosa</italic> extract allows us to visualize its powerful inhibition for the subunits of the proteasome.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Preparation of Extracts from <italic>Inula viscosa</italic></title><p>
<italic>Inula viscosa</italic> L. was collected from the regions of Taza, Morocco. Thereafter, it was dried away from light and humidity at room temperature. Once dried, the plant material was reduced to powder using electric propeller mill and extract under reflux. The method used is called maceration. Ethanol extraction was performed at the ratio of 10% (<italic>w</italic>/<italic>v</italic>) for 3&#x02009;h under agitation [<xref rid="B19" ref-type="bibr">19</xref>]. The separation of the ethanol from the extract of <italic>Inula viscosa</italic> was carried out using a rotary evaporator at a temperature of 33&#x000b0;C and at 78&#x02009;rpm. Once obtained, the extract is stored at 4&#x000b0;C in the dark until use.</p></sec><sec id="sec2.2"><title>2.2. Animals</title><p>Female Swiss albino mice, 8&#x02013;10 weeks old of age and weighing (25 &#x000b1; 30&#x02009;g), were obtained from the pet shop of our institute and were housed in polypropylene cages. The animals were acclimatized for 1 week before starting the experiment. Mice were fed with commercially available food pellets and tap water ad libitum and maintained on standard housing conditions under a controlled atmosphere with 12&#x02009;:&#x02009;12&#x02009;h light/dark cycles with ambient temperature of 25 &#x000b1; 5&#x000b0;C, and humidity at 50 &#x000b1; 10%. Animal handling and experimental protocol were conducted according to the guidelines of the Institutional Ethical Committee (IEC).</p></sec><sec id="sec2.3"><title>2.3. Experimental Groups of Mice</title><p>In order to determine the nonlethal dose of the <italic>Inula viscosa</italic> plant extract, a toxicity test was performed. In fact, decreasing concentrations and/or volumes of the extract were used until obtaining a dose that does not cause lethality on mice. This dose was then used in the same mouse for 4 days, a period chosen to mimic the protocol used during the treatment with the extracts. The volume used was 25&#x02009;<italic>&#x003bc;</italic>L and adjusted to 100&#x02009;<italic>&#x003bc;</italic>L using phosphate-buffered saline (PBS). The anticancer potential of the prepared extract was evaluated by administering 100&#x02009;<italic>&#x003bc;</italic>L of the extract to mice as skin cancer was in parallel induced.</p><p>To induce carcinogenesis in mice, approximately 2.5&#x02009;cm<sup>2</sup> of dorsal body wall hair was removed by shaving with electric clippers followed by the application of depilatory cream one day prior to the beginning of the experiment. Thereafter, the mice were initiated by a single topical application of DMBA (100&#x02009;<italic>&#x003bc;</italic>g/100&#x02009;<italic>&#x003bc;</italic>L acetone) on shaved dorsal skin (initiation phase) and, 2 weeks later, promoted by twice-weekly topically applications of 1% croton oil (1&#x02009;<italic>&#x003bc;</italic>L/100&#x02009;<italic>&#x003bc;</italic>L acetone) at the same site for 20 weeks (promotion phase). The normal control mice received only acetone in place of DMBA and croton oil [<xref rid="B20" ref-type="bibr">20</xref>]. Animals were divided into five groups (10 mice/group) as follows: Group 1: treated by intraperitoneal injection of <italic>Inula viscosa</italic> extract during the initiation phase; Group 2: treated by intraperitoneal injection of <italic>Inula viscosa</italic> extract during the promotion phase; Group 3: treated by intraperitoneal injection of <italic>Inula viscosa</italic> extract during the initiation and promotion phase; Group 4: treated by intraperitoneal injection of PBS (tumor control); and Group 5: treated by intraperitoneal injection of PBS (normal control).</p><p>The mice in group 1 were treated with intraperitoneal injection of 100&#x02009;<italic>&#x003bc;</italic>L of the prepared extracts, one day before the initiation phase, 30&#x02009;min before initiation, and one day after the initiation phase.</p><p>The mice in group 2 were treated with intraperitoneal injection of 100&#x02009;<italic>&#x003bc;</italic>L of the prepared extracts, one day before the promotion phase, 30&#x02009;min before the promotion, and one day after the promotion phase.</p><p>The mice of group 3 were treated with intraperitoneal injection of 100&#x02009;<italic>&#x003bc;</italic>L of the prepared extracts, one day before the initiation phase, 30&#x02009;min before the initiation, and one day after the initiation phase.</p><p>Mice in the group 4 (tumor control) and group 5 (normal control) were treated with 100&#x02009;<italic>&#x003bc;</italic>L of PBS and around the days of DMBA and croton oil application with intraperitoneal injections carried out in the same way as in the mice treated with the extracts.</p></sec><sec id="sec2.4"><title>2.4. Morphologic Observation of Papilloma Development</title><p>During the 20 weeks of experiments, mice were observed daily for the appearance of skin papillomas tumor, volume, and body weights, which were recorded at interval of 7 days until sacrifice. Tumors were counted, measured, and scored weekly as clinically apparent papillomas (typically well-demarcated, asymmetrical, pedunculated, or dome-shaped papules, without erosion or ulceration) or clinically apparent carcinomas (poorly demarcated, asymmetrical, sessile, or dome-shaped papules with erosion or ulceration). Tumors were evaluated by visual inspection to the experimental groups.</p></sec><sec id="sec2.5"><title>2.5. Histological Evaluation</title><p>Collected skins (tumors and normal skin) were fixed in 10% neutral formalin for 24&#x02009;h and passed through ascending grades of ethyl alcohol starting from 60% to 95%. The dehydrated tissues were then soaked in toluene and then transferred to molten paraffin (60&#x000b0;C), which was poured into metal molds, and the tissues were set accordingly. Serial microtome sections in the form of paraffin ribbon were made at a thickness of 4&#x02009;<italic>&#x003bc;</italic>m. The tissues were then floated in a tray covering lukewarm water (58&#x000b0;C) to stretch the tissues. Tissue sections (3&#x02013;4&#x02009;<italic>&#x003bc;</italic>m) were taken for hematoxylin&#x02013;eosin (HE) staining and histopathological evaluation [<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec id="sec2.6"><title>2.6. Cell Lysis</title><p>The serum is recovered from a mouse blood sample and gradually cooled to 4&#x000b0;C and -20&#x000b0;C. Lymphocyte the pellet is recovered by lysis of red blood cells. First, we proceed to the preparation of the white cell pellet. Briefly, red cells of the blood samples were broken by adding a solution of Tris-EDTA (20/5) to whole blood after centrifugation, the supernatant is removed, and this procedure was repeated until a clear cell layer is obtained. Thereafter, 200&#x02009;mU/L of lysis buffer (10&#x02009;mM KCl, 10&#x02009;mM NaCl, 10&#x02009;mM HEPES, 1&#x02009;mM EDTA pH&#x02009;7.1, 0.1&#x02009;mM DTT, and 1% Triton, supplemented with protease inhibitors (PMSF 2&#x02009;nM)) was added on each sample. The cells are disrupted with alternating periods of 20&#x02009;s break with 30&#x02009;s rest to avoid excessive heating of samples that can cause denaturation of enzymes [<xref rid="B22" ref-type="bibr">22</xref>]. The protocol is repeated 3 times. The extracts obtained may be stored at -20&#x000b0;C until their use.</p></sec><sec id="sec2.7"><title>2.7. Measurement of Proteasome Activity</title><p>The catalytic activity (chymotrypsin-like) of the 20S proteasome on the fluorogenic peptide Leu-Leu-succinyl-Val-Tyr-Amido-4-methylcoumarin (Suc-LLVY-AMC) was determined after substrate incubation with the sample at 37&#x000b0;C for over 3&#x02009;h. The fluorescence emitted after cleavage of the AMC is determined using a Fluorometer (Hoefer Scientific Instruments). The excitement of peptides, coupled at the AMC, is done through a 360/40&#x02009;nm filter at a wavelength between 340&#x02009;nm and 380&#x02009;nm with a maximum of 360&#x02009;nm. The fluorescence emitted after digestion of peptides coupled to the AMC reads on the 460/40&#x02009;nm filter. To convert the fluorescence unit (FU) issued <italic>&#x003bc;</italic>mol of used fluorophores, a standard AMC range was established from a stock solution of AMC at 10-3&#x02009;m. The excitement of the AMC is done at a wavelength of 360/40&#x02009;nm, and the signal is then recovered on the 460/40&#x02009;nm filters [<xref rid="B22" ref-type="bibr">22</xref>].</p></sec><sec id="sec2.8"><title>2.8. Docking Studies</title><p>For this study, plant compounds were collected from the PubChem database. A total of 14 molecules are reported to be isolated from <italic>Inula viscosa</italic> L.; these molecules were considered for the study of molecular docking. Therefore, the X-ray crystalline 3D structure of the proteasome 20S (PDB: 4R3O, resolution 2.60&#x02009;&#x000c5;) was obtained from the Data Bank Protein [<xref rid="B23" ref-type="bibr">23</xref>] and prepared by Discovery Studio 2020 [<xref rid="B24" ref-type="bibr">24</xref>] by removing water molecules, and polar hydrogen was added, the 4r3o PDB file containing 28 chains, 2 chains (1,M) for <italic>&#x003b2;</italic><sub>1</sub>, 2 chains (K,Y) for <italic>&#x003b2;</italic><sub>2</sub>, and 2 chains (L,Z) for <italic>&#x003b2;</italic><sub>5</sub>. The rest of the chains are removed and only the <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub> chains kept to speed up and simplify the calculations.</p><p>The three molecules selected according to the virtual screening were used to perform molecular docking against the target PDB (4R3O). The AutoDock Vina [<xref rid="B25" ref-type="bibr">25</xref>] and MGLTools programs [<xref rid="B26" ref-type="bibr">26</xref>], were used with default settings. Carfilzomib was considered a positive control.</p></sec><sec id="sec2.9"><title>2.9. Virtual Screening</title><p>High-speed virtual screening was performed using the iGEMDOCK (Generic Evolution Method for Docking) program [<xref rid="B27" ref-type="bibr">27</xref>]. The <italic>in silico</italic> screening of 14 compound extracted from <italic>Inula viscosa</italic> was performed using the PDB code of the targets (PDB ID: 4R3O); the screening score, which is based on total energy calculations (total&#x02009;energy = van&#x02009;der&#x02009;Waals&#x02009;(VdW) + hydrogen&#x02009;bond&#x02009;(HBond) + electrostatic), was calculated using iGEMDOCK v2.1.11.</p><p>The standard parameters used for screening, population size, generations, and number of solutions, were set at 300, 70, and 2, respectively. Energy-based results were analyzed, and 9 potential inhibitors were selected based on stability for further detailed analyses.</p></sec><sec id="sec2.10"><title>2.10. Visualization and Analysis of Results</title><p>The results were visualized by the Discovery Studio Visualizer [<xref rid="B28" ref-type="bibr">28</xref>] and PyMOL [<xref rid="B30" ref-type="bibr">30</xref>]. The results of the molecules showed an interesting docking score, and their positioning inside the active site was also compared as well as type of interactions established by each molecule inside the active site.</p></sec><sec id="sec2.11"><title>2.11. Prediction of ADMET</title><p>To develop a drug, several steps are necessary, starting with target identification and ending with ADMET prediction. Therefore, the early determination of these properties is very necessary to reduce the cost and also the time of the drug discovery process. These parameters include the absorption of the drug (absorption), the distribution in the body (distribution), the biochemical remodeling (metabolism), excretion, and toxicity. In this perspective, the best three molecules selected on the basis of their score energy and which showed better affinity have been evaluated to determine these pharmacokinetic parameters <italic>in silico</italic>, to prevent the failure of these compounds in clinical trials and increase their chances of reaching the stage of drug candidates in the future [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>].</p></sec><sec id="sec2.12"><title>2.12. Statistical Data Analysis</title><p>All data obtained are represented as the mean &#x000b1; standard&#x02009;error&#x02009;of&#x02009;the&#x02009;mean (SEM). The results were computed statistically (IBM SPSS statistics 20 Software Package) using one-way ANOVA. In all tests, the level of statistical significance was set at <italic>p</italic> &#x0003c; 0.05.</p></sec></sec><sec id="sec3"><title>3. Results and Discussion</title><sec id="sec3.1"><title>3.1. Skin Papillomas Assessments</title><p>In order to evaluate the antitumor potential of <italic>Inula viscosa</italic> extract, three groups of mice were used, including a control group, a carcinogenesis group, and a group treated with <italic>Inula viscosa</italic> extract during the tumor initiation and promotion phases (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The skin of the control mice did not develop any papilloma growth, whereas all mice in the carcinogenesis group demonstrated increasing formation of papillomas. Therefore, the mice treated with intraperitoneal injections of <italic>Inula viscosa</italic> extract demonstrated a reduced occurrence of the growth of papilloma compared to the carcinogen mice. Moreover, the best chemopreventive action of <italic>Inula viscosa</italic> was observed in mice in which extract treatment was performed before and after the induction of skin carcinogenesis.</p></sec><sec id="sec3.2"><title>3.2. Effect of the <italic>Inula viscosa</italic> during the Initiation Phase</title><p>The carcinogenic mice (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>) not treated with plant extract showed a mean number of papillomas of 16 &#x000b1; 2.15 after 20 weeks. However, a significant reduction of papillomas was observed in the group treated with <italic>Inula viscosa</italic> (6 &#x000b1; 1.5). Therefore, the control mice did not produce any papilloma on their skin but 100% of the DMBA-treated mice developed papilloma growth until the end of 20 weeks (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). <italic>Inula viscosa</italic>-treated groups of mice demonstrated slower growth of papillomas (37.5%).</p><p>In this study, we found that appearance of papillomas depends on the type of treatment. Indeed, it was noticed that the appearance of the tumors increases in number and size with time. On the other hand, for the control mice, no lesions or tissue damage were observed, and the appearance of papillomas is very similar to the control mice.</p></sec><sec id="sec3.3"><title>3.3. Effect of the <italic>Inula viscosa</italic> during the Promotion Phase</title><p>To evaluate the effect of <italic>Inula viscosa</italic> extract on tumor development in mice, abdominal injections were applied during the promotion phase. The carcinogenic mice (<xref ref-type="fig" rid="fig3">Figure 3(a)</xref>) not treated with plant extract showed average number of papillomas of 16 &#x000b1; 2.15 after 20 weeks. Furthermore, a significant reduction of papillomas was observed in the group treated with <italic>Inula viscosa</italic> (5 &#x000b1; 1.25). Therefore, the control mice did not produce any papilloma on their skin but 100% of the DMBA-treated mice developed papilloma growth until the end of 20 weeks. <italic>Inula viscosa</italic>-treated groups of mice (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref>) demonstrated slower growth of papillomas (31.25%).</p></sec><sec id="sec3.4"><title>3.4. Effect of the <italic>Inula viscosa</italic> during the Initiation and Promotion Phase</title><p>The treatment of carcinogenic mice with <italic>Inula viscosa</italic> extract during the initiation and promotion phase showed a reduction of the tumor load (number of papillomas/mice); the mice stabilized in 2 papillomas whereas the number of papillomas in carcinogenic mice were 16 &#x000b1; 2.15 (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>) with inhibition growth of papillomas, which can be as much as 87.5%. (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>) after 20 weeks of treatment. Therefore, the results obtained clearly show the presence of a protective effect due to the extract treatment. Our results are in agreement with some studies [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. Phytotherapy has proved to be very promising. Indeed, <italic>in vivo</italic> study showed that treatment with gallic acid induces the inhibition of cancer cell proliferation, through the suppression of DMBA action and croton oil by modulating the antioxidant and MMP-2/MMP-9 in Swiss albino mice [<xref rid="B32" ref-type="bibr">32</xref>]. In contrast, the results obtained suggest that extracts from <italic>Inula viscosa</italic> have a strong antitumor effect effective in preventing DMBA-induced skin cancer. Hence, this observed difference could be explained by the fact that the process of carcinogenesis is multifactorial and made up of several steps. Therefore, for a good control, the treatment should be applied before, during, and after the installation of cancer.</p><p>DMBA is a very potent carcinogen, which can lead to mutations in cellular DNA. The critical event in the initiation of carcinogenesis by DMBA is the conversion of DMBA to reactive oxygen species by a set of enzymes that metabolize xenobiotics. Croton oil is rich in phorbol esters; it can act as tumor promoters by activating protein kinase C. The increase in the concentration of active oxygen, organic peroxides, and radicals in cells can also promote neoplastic growth of initiated cells [<xref rid="B34" ref-type="bibr">34</xref>]. The key mechanism of action of the majority of chemopreventive agents is their potential to prevent either the metabolic activation of procarcinogens or the neutralization of reactive metabolites and free radicals generated during the process of carcinogenesis [<xref rid="B35" ref-type="bibr">35</xref>]. In cancer cells, chemopreventive agents exert cytotoxicity in cancer cells and target different stages of cancer progression by inhibiting angiogenesis, preventing metastasis, and inducing apoptosis [<xref rid="B36" ref-type="bibr">36</xref>]. The ability of <italic>Inula viscosa</italic> bioactive molecules to selectively activate apoptotic cascades in cancer cells, inhibit the activation of carcinogens, and prevent further promotion could be the explanation for its demonstrated antitumor effects.</p></sec><sec id="sec3.5"><title>3.5. Histopathological Findings</title><p>Skin is made of three large layers: epidermis, dermis, and hypodermis. This is made up of a variety of distinct cell types, the primary components being keratinocytes and melanocytes. Keratinocytes, which compose 95% of the epidermis, are organized into four layers. The inner layer is the stratum germinativum (stratum basale, basal layer), from which column-shaped keratinocytes divide to migrate to the next layer. Two layers of small, undifferentiated epidermis cells differentiate into different layers following exposure to a local carcinogen. The papillary layer in the dermis is a subepithelial layer of tightly arranged, fine collagenous fiber and fiber bundles. The dermis reticular layer comprises coarse collagenous fibers of considerable thickness [<xref rid="B37" ref-type="bibr">37</xref>]. Those are the characteristics control mice that showed a normal distribution of different layers of the skin: no hyperplasia and no cell proliferation was observed (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>). In contrast, analysis of histological sections of mice developing tumors (<xref ref-type="fig" rid="fig5">Figure 5(b)</xref>) showed a typical change in the skin illustrated by thickening of the epidermis, epidermal cells invasion into the dermis, hyperkeratosis, and acanthosis of the epidermis. Therefore, histological sections of mice treated with the <italic>Inula viscosa</italic> plant extract (<xref ref-type="fig" rid="fig5">Figure 5(c)</xref>) showed normal structure and architecture of the skin with mild to moderate prevention of skin carcinogenesis.</p><p>Nonetheless, according to these data, it can be proposed that our extract exerts its antitumor effects either at the initiation phase by protecting the DNA from mutations caused by the action of DMBA [<xref rid="B32" ref-type="bibr">32</xref>] or during the promotion phase through the neutralization of the microenvironment of free radicals [<xref rid="B33" ref-type="bibr">33</xref>], which favor the setting up of a carcinogenesis process. The results obtained showed that our extract exerts their effect during both phases. This translates into the best reduction in the number of papillomas observed when the mice are treated during both phases (initiation and promotion) compared to those treated during the initiation phase alone, and/or the promotion phase alone.</p></sec><sec id="sec3.6"><title>3.6. Measurement of Chymotrypsin-Like Proteasomal Activity</title><p>It can be seen from <xref ref-type="fig" rid="fig6">Figure 6</xref> that at the serum level, the catalytic activity of the proteasome of mice from groups treated with <italic>Inula viscosa</italic> extracts (691.14 &#x000b1; 8.55 FU) was significantly lower (<italic>p</italic> &#x02264; 0.001) compared to that measured in mice from the carcinogenesis group (1294 &#x000b1; 34.1 FU), whereas the lowest catalytic activity was measured in the control group (455.63 &#x000b1; 22.75 FU). The intracellular proteasome catalytic activity of mice in <italic>Inula viscosa</italic>-treated groups (1020 &#x000b1; 18.1 FU) was lower compared to that measured in the carcinogenesis group (1612 &#x000b1; 30.2 FU), while mice in the control group still showed the lowest proteasome catalytic activity (733 &#x000b1; 36.65 FU).</p><p>Therefore, the catalytic activity of proteasome at serum and intracellular levels was very important in mice of the carcinogenic group than in mice of the groups treated with <italic>Inula viscosa</italic> extract. These data are in agreement with several findings using the approach of proteasome inhibition by chemically synthesized inhibitors [<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>]. Indeed, Lavabre et al. in 2001, in a study of solid tumors, showed a total regression of the tumors accompanied by a decrease in the concentration of proteasome as well as its catalytic activity with treatment with chemically synthesized proteasome inhibitors such as epoxomicin and bortezomib. Furthermore, subsequent studies performed in our laboratory by Filali et al. [<xref rid="B22" ref-type="bibr">22</xref>] on Moroccan patients with hematological malignancies suggest that treatment with proteasome inhibitors, in addition to tumor regression, induces a decrease in proteasome concentration and catalytic activity. Hence, it can be considered that proteasome could be a new factor in the diagnosis and follow-up of treatment in cancer diseases [<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>]. Based on these data, the proteasome could be a key factor in the neoplastic differentiation of cells, a novel cancer biomarker, and a key element in the clinical follow-up of patients with skin cancer. Hence, the analysis of the catalytic activity provides information on the functionality of the complex and consequently on its molecular nature at the serum and subcellular levels. Several studies [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>] demonstrate that only the inhibition of chymotrypsin-like activity, carried by the <italic>&#x003b2;</italic>5 subunits, is sufficient to allow a significant reduction in the rate of protein degradation while the inactivation of the other sites, trypsin-like and PGPH, has little effect on total proteolysis.</p><p>Treatments based on the <italic>Inula viscosa</italic> extract have been shown to be effective in the treatment of skin carcinoma. In addition, this extract contains phenolic compounds and/or flavonoids known for their antioxidant effects [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>] and contains bioactive molecules with structures similar and close to those of chemically synthesized proteasome inhibitors, capable of effectively inhibiting the ubiquitin proteasome complex, more specifically the catalytic activity of the latter. Based on these data, it can be concluded that treatment with <italic>Inula viscosa</italic> extract causes a regression of the tumor load with a decrease in serum and intracellular activities.</p><p>Consequently, the treatment with the plant extract of <italic>Inula viscosa</italic> revealed significant results and could constitute therefore a new approach for the treatment of skin carcinoma.</p></sec><sec id="sec3.7"><title>3.7. Virtual Screening</title><p>The analysis of the type of binding and the calculation of the energy score of 14 compounds extracted from <italic>Inula viscosa</italic> with the proteasome 20S (PDB: 4R3O) allows the selection of the best compounds. Three molecules were selected on the basis of their low energy values. The energy values of tomentosin, inuviscolide, and isocosticacid are -65.53, -64.53, and -60.68, respectively, for <italic>&#x003b2;</italic><sub>1</sub>, and -62.63, -62.09, and -57.90 for <italic>&#x003b2;</italic><sub>2</sub>, and -61.23, 62.41, and 60.37 for <italic>&#x003b2;</italic><sub>5</sub> as shown in (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.8"><title>3.8. Molecular Docking</title><p>The three molecules obtained after the high throughput screening were used for further study using molecular docking to study their stability and interactions with the <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub>. Carfilzomib was considered a positive control.</p><p>The binding energy of the selected candidates ranged from -6.3 to -6.1&#x02009;kcal/mol for <italic>&#x003b2;</italic><sub>1</sub> and from -6.5 to -6&#x02009;kcal/mol for <italic>&#x003b2;</italic><sub>2</sub>, and from 6.2&#x02009;kcal/mol to 6&#x02009;kcal/mol for <italic>&#x003b2;</italic><sub>5</sub>, with all three molecules having higher energy than carfilzomib (-5.2&#x02009;kcal/mol) for the three targets, as shown in (<xref rid="tab2" ref-type="table">Table 2</xref>). The resulting molecule, all three compounds, had a greater affinity with the active site of <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub>.</p></sec><sec id="sec3.9"><title>3.9. Visualization and Analysis of Results</title><p>We visualized the positioning of these three molecules with <italic>&#x003b2;</italic><sub>5</sub> (<xref ref-type="fig" rid="fig7">Figure 7</xref>); also, the one of carfilzomib shows the docking results and the types of interactions with the amino acids within the active site.</p><p>The molecular docking results are shown in (<xref ref-type="fig" rid="fig7">Figure 7</xref>) which indicate that tomentosin, inuviscolide, isocosticacid, and carfilzomib compounds are stabilized in the pocket of the <italic>&#x003b2;</italic><sub>5</sub> receptor by various interactions. The three compounds that are the most active molecules are stabilized by hydrogen-bonding interactions, pi-alkyl interactions, carbon hydrogen, pi-sigma carbon bonds, and Van der Waals interactions (<xref rid="tab3" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3.10"><title>3.10. ADMET Properties</title><p>The pharmacokinetic properties of three compound have been determined; the compounds are adsorbed when they fulfil the Lipinski rule, where a good drug should have a LogP partition coefficient of less than 5, a weight (MW) of less than 500&#x02009;Da, number of HBA &#x0003c; 10, number of HBD &#x0003c; 5, and rotational bonds of less than 10 [<xref rid="B46" ref-type="bibr">46</xref>] (<xref rid="tab4" ref-type="table">Table 4</xref>).</p><p>The objective of the ADMET preclinical study is to eliminate weak candidates and focus on successful drug candidates. This study addresses the applicability of the three compounds proposed as anticancer agents using the virtual properties, absorption, distribution, metabolism, excretion, and toxicity, which are crucial actors in drug development. The pharmacokinetic properties have been calculated using admetSAR. Therefore, penetration of the blood-brain barrier (BBB), human intestinal absorption (HIA), Caco-2 cell permeability, and AMES test are used to specify drug-like properties. Penetration of the blood-brain barrier (BBB) is an important property since it determines whether or not drugs can cross the blood-brain barrier and also exert its effect on the brain [<xref rid="B47" ref-type="bibr">47</xref>].</p><p>Compounds with a BBB less than 1 are considered poorly distributed in the brain. The BBB permeability results in (<xref rid="tab5" ref-type="table">Table 5</xref>) show a nonpenetrating BBB for novel anticancer compounds. The molecule with less than 30% absorbance is considered poorly absorbed, indicating that all compounds tested could be absorbed from the human gut; however, the cytochrome P450 subtypes CYP2D6 and CYP3A4 indicate that the compounds inuviscolide and tomentosin could not be substrates or inhibitors for the two major subtypes and therefore would likely not be metabolized. Fortunately, our best candidate compound isocosticacid showed no acute toxicity and no mutagenic effects compared to the Ames test data (<xref rid="tab5" ref-type="table">Table 5</xref>).</p></sec></sec><sec id="sec4"><title>4. Conclusions and Perspectives</title><p>In conclusion, this study revealed that the treatment with <italic>Inula viscosa</italic> extract shows a strong inhibition for the appearance of tumors in the form of papillomas, which is clearly demonstrated by the decreased activity at the serum and intracellular levels. Therefore, the docking studies remain a very effective tool and essential study to identify the degrees of structural similarity and the percentage of predictive inhibition of proteasome subunits by bioactive molecules. The data obtained clearly show that <italic>Inula viscosa</italic> extract contains bioactive molecules with a much greater proteasome inhibition potentials than the chemically synthesized inhibitors and could be better new candidates in targeted therapy against skin carcinoma. However, it would be interesting to isolate and purify these molecules particularly (tomentosin, inuviscolide, and isocosticacid), in order to test them, in a later work, on other cancerous diseases.</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability</title><p>All used data in this study were cited in the manuscript.</p></sec><sec><title>Additional Points</title><p>The proteasome inhibition for anticancer therapy, particularly by natural compounds, has produced distinct and promising outcomes of cancer treatment. The use of a proteasome inhibitor might be an effective strategy in the treatment of skin cancer. <italic>Inula viscosa</italic> (L.) Aiton (Compositae) is a medicinal plant distributed in different regions of the Mediterranean Basin. Therefore, the plant has been used in traditional medicine for treatment of different diseases, including cancer treatment. <italic>In vivo</italic> studies showed that <italic>Inula viscosa</italic> extracts inhibit the development of skin carcinoma induced by DMBA in the mouse. Docking studies showed that <italic>Inula viscosa</italic> extract contains bioactive molecules with a much greater proteasome inhibition potentials than the chemically synthesized inhibitors and could be better new candidates in targeted therapy against skin carcinoma.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Schwesinger</surname><given-names>C.</given-names></name></person-group><article-title>The ubiquitin-proteasome system in kidney physiology and disease</article-title><source><italic toggle="yes">Nature Reviews. Nephrology</italic></source><year>2019</year><volume>15</volume><issue>7</issue><fpage>393</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/s41581-019-0148-1</pub-id><pub-id pub-id-type="other">2-s2.0-85065214250</pub-id><?supplied-pmid 31036905?><pub-id pub-id-type="pmid">31036905</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koper-Lenkiewicz</surname><given-names>O. M.</given-names></name><name><surname>Kami&#x00144;ska</surname><given-names>J.</given-names></name><name><surname>Resze&#x00107;</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2020</year><volume>15</volume><issue>9, article e0238406</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0238406</pub-id><?supplied-pmid 32886667?><pub-id pub-id-type="pmid">32886667</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>K.</given-names></name><name><surname>Diao</surname><given-names>P.</given-names></name><name><surname>Tang</surname><given-names>P.</given-names></name></person-group><article-title>Potential use of chymotrypsin-like. Proteasomal activity as a biomarker for prostate cancer</article-title><source><italic toggle="yes">Oncology Letters</italic></source><year>2018</year><volume>15</volume><issue>4</issue><fpage>5149</fpage><lpage>5154</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.7936</pub-id><pub-id pub-id-type="other">2-s2.0-85042634838</pub-id><?supplied-pmid 29552150?><pub-id pub-id-type="pmid">29552150</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voutsadakis</surname><given-names>I. A.</given-names></name></person-group><article-title>Proteasome expression and activity in cancer and cancer stem cells.</article-title><source><italic toggle="yes">Tumor Biology</italic></source><year>2017</year><volume>39</volume><issue>3, article 1010428317692248</issue><pub-id pub-id-type="doi">10.1177/1010428317692248</pub-id><pub-id pub-id-type="other">2-s2.0-85016923851</pub-id><?supplied-pmid 28345458?><pub-id pub-id-type="pmid">28345458</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basler</surname><given-names>M.</given-names></name><name><surname>Groettrup</surname><given-names>M.</given-names></name></person-group><article-title>Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy</article-title><source><italic toggle="yes">Genes and Immunity</italic></source><year>2020</year><volume>21</volume><issue>5</issue><fpage>273</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/s41435-020-00109-1</pub-id><?supplied-pmid 32839530?><pub-id pub-id-type="pmid">32839530</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Linder</surname><given-names>S.</given-names></name><name><surname>Bazzaro</surname><given-names>M.</given-names></name></person-group><article-title>Drug development targeting the ubiquitin&#x02013;proteasome system (UPS) for the treatment of human cancers</article-title><source><italic toggle="yes">Cancers</italic></source><year>2020</year><volume>12</volume><issue>4</issue><fpage>p. 902</fpage><pub-id pub-id-type="doi">10.3390/cancers12040902</pub-id><?supplied-pmid 32272746?><pub-id pub-id-type="pmid">32272746</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Meul</surname><given-names>T.</given-names></name><name><surname>Meiners</surname><given-names>S.</given-names></name></person-group><article-title>Exploring the proteasome system: a novel concept of proteasome inhibition and regulation</article-title><source><italic toggle="yes">Pharmacology &#x00026; Therapeutics</italic></source><year>2020</year><volume>211, article 107526</volume><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107526</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soave</surname><given-names>C. L.</given-names></name><name><surname>Guerin</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Dou</surname><given-names>Q. P.</given-names></name></person-group><article-title>Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing</article-title><source><italic toggle="yes">Cancer Metastasis Reviews</italic></source><year>2017</year><volume>36</volume><issue>4</issue><fpage>717</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1007/s10555-017-9705-x</pub-id><pub-id pub-id-type="other">2-s2.0-85031763530</pub-id><?supplied-pmid 29047025?><pub-id pub-id-type="pmid">29047025</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabavi</surname><given-names>S. F.</given-names></name><name><surname>Atanasov</surname><given-names>A. G.</given-names></name><name><surname>Khan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: lessons learned from clinical trials</article-title><source><italic toggle="yes">Cancer Letters</italic></source><year>2018</year><volume>434</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.07.018</pub-id><pub-id pub-id-type="other">2-s2.0-85050251492</pub-id><?supplied-pmid 30030139?><pub-id pub-id-type="pmid">30030139</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hedayat</surname><given-names>K. M.</given-names></name><name><surname>Lapraz</surname><given-names>J.-C.</given-names></name><name><surname>Schuff</surname><given-names>B.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hedayat</surname><given-names>K. M.</given-names></name><name><surname>Lapraz</surname><given-names>J.-C.</given-names></name><name><surname>Schuff</surname><given-names>B.</given-names></name></person-group><article-title>Chapter 5 - medicinal plants in clinical practice</article-title><source><italic toggle="yes">The Theory of Endobiogeny</italic></source><year>2020</year><publisher-name>Academic Press</publisher-name><fpage>57</fpage><lpage>60</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumisiriza</surname><given-names>H.</given-names></name><name><surname>Sesaazi</surname><given-names>C. D.</given-names></name><name><surname>Olet</surname><given-names>E. A.</given-names></name><name><surname>Kembabazi</surname><given-names>O.</given-names></name><name><surname>Birungi</surname><given-names>G.</given-names></name></person-group><article-title>Medicinal plants used to treat "African" diseases by the local communities of Bwambara sub-county in Rukungiri District, Western Uganda</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2021</year><volume>268, article 113578</volume><pub-id pub-id-type="doi">10.1016/j.jep.2020.113578</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hedayat</surname><given-names>K. M.</given-names></name><name><surname>Lapraz</surname><given-names>J.-C.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hedayat</surname><given-names>K. M.</given-names></name><name><surname>Lapraz</surname><given-names>J.-C.</given-names></name></person-group><article-title>Chapter 16 - Introduction to the usage of medicinal plants</article-title><source><italic toggle="yes">The Theory of Endobiogeny</italic></source><year>2019</year><publisher-name>Academic Press</publisher-name><fpage>255</fpage><lpage>266</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brullo</surname><given-names>S.</given-names></name><name><surname>de Marco</surname><given-names>G.</given-names></name></person-group><article-title>Taxonomical revision of the genus Dittrichia (Asteraceae)</article-title><source><italic toggle="yes">Portugaliae Acta Biologica</italic></source><year>2000</year><volume>19</volume><issue>1/4</issue><fpage>341</fpage><lpage>354</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbetti</surname><given-names>P.</given-names></name><name><surname>Chiappini</surname><given-names>I.</given-names></name><name><surname>Fardella</surname><given-names>G.</given-names></name><name><surname>Menghini</surname><given-names>A.</given-names></name></person-group><article-title>A new eudesmane acid <italic>fromDittrichia</italic> (Inula) viscosa</article-title><source><italic toggle="yes">Planta Medica</italic></source><year>1985</year><volume>51</volume><issue>5</issue><fpage>p. 471</fpage><pub-id pub-id-type="doi">10.1055/s-2007-969564</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qura&#x02019;n</surname><given-names>S.</given-names></name></person-group><article-title>Ethnopharmacological survey of wild medicinal plants in Showbak, Jordan</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2009</year><volume>123</volume><issue>1</issue><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2009.02.031</pub-id><pub-id pub-id-type="other">2-s2.0-64249109576</pub-id><pub-id pub-id-type="pmid">19429338</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Merdamert-Bozyel</surname><given-names>E.</given-names></name><name><surname>Bozyel</surname><given-names>M. E.</given-names></name><name><surname>Demir</surname><given-names>N.</given-names></name></person-group><source><italic toggle="yes">Antioxidant activity and protective effect on DNA cleavage of extracts from Inula viscosa (L.) Aiton</italic></source><year>2017</year><publisher-name>IVEK 3rd International Convention of Pharmaceutical and Pharmacies</publisher-name></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Shalom</surname><given-names>R.</given-names></name><name><surname>Bergman</surname><given-names>M.</given-names></name><name><surname>Grossman</surname><given-names>S.</given-names></name><name><surname>Azzam</surname><given-names>N.</given-names></name><name><surname>Sharvit</surname><given-names>L.</given-names></name><name><surname>Fares</surname><given-names>F.</given-names></name></person-group><article-title>
<italic>Inula viscosa</italic> extract inhibits growth of colorectal cancer cells <italic>in vitro</italic> and <italic>in vivo</italic> through induction of apoptosis</article-title><source><italic toggle="yes">Frontiers in Oncology</italic></source><year>2019</year><volume>9</volume></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kheyar-Kraouche</surname><given-names>N.</given-names></name><name><surname>da Silva</surname><given-names>A. B.</given-names></name><name><surname>Serra</surname><given-names>A. T.</given-names></name><name><surname>Bedjou</surname><given-names>F.</given-names></name><name><surname>Bronze</surname><given-names>M. R.</given-names></name></person-group><article-title>Characterization by liquid chromatography&#x02013;mass spectrometry and antioxidant activity of an ethanolic extract of <italic>Inula viscosa</italic> leaves</article-title><source><italic toggle="yes">Journal of Pharmaceutical and Biomedical Analysis</italic></source><year>2018</year><volume>156</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2018.04.047</pub-id><pub-id pub-id-type="other">2-s2.0-85046636525</pub-id><?supplied-pmid 29730339?><pub-id pub-id-type="pmid">29730339</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messaoudi</surname><given-names>M.</given-names></name><name><surname>Chahmi</surname><given-names>N.</given-names></name><name><surname>El Mzibri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cytotoxic effect and chemical composition of <italic>Inula viscosa</italic> from three different regions of Morocco</article-title><source><italic toggle="yes">European Journal of Medicinal Plants</italic></source><year>2016</year><volume>16</volume><issue>4</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.9734/EJMP/2016/28340</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>I.</given-names></name><name><surname>Saha</surname><given-names>T.</given-names></name></person-group><article-title>Effect of garlic on lipid peroxidation and antioxidation enzymes in DMBA-induced skin carcinoma</article-title><source><italic toggle="yes">Nutrition</italic></source><year>2009</year><volume>25</volume><issue>4</issue><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2008.10.014</pub-id><pub-id pub-id-type="other">2-s2.0-60749085613</pub-id><?supplied-pmid 19084378?><pub-id pub-id-type="pmid">19084378</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>E.</given-names></name><name><surname>Sadaba</surname><given-names>M. C.</given-names></name><name><surname>Ortiz</surname><given-names>A. I.</given-names></name><etal/></person-group><article-title>Tumoricidal activity of lauryl gallate towards chemically induced skin tumours in mice</article-title><source><italic toggle="yes">British Journal of Cancer</italic></source><year>2003</year><volume>88</volume><issue>6</issue><fpage>940</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600805</pub-id><pub-id pub-id-type="other">2-s2.0-0037464298</pub-id><?supplied-pmid 12644834?><pub-id pub-id-type="pmid">12644834</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filali</surname><given-names>H.</given-names></name><name><surname>Quessar</surname><given-names>A.</given-names></name><name><surname>Henry</surname><given-names>L.</given-names></name><name><surname>El-Antri</surname><given-names>S.</given-names></name><name><surname>Aboudkhil</surname><given-names>S.</given-names></name></person-group><article-title>Serum and subcellular proteasome in Moroccan patients reached hematological malignancies</article-title><source><italic toggle="yes">International Journal of Medical &#x00026; Health Sciences</italic></source><year>2015</year><volume>4</volume><issue>2</issue><fpage>217</fpage><lpage>224</lpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="other"><collab>Bank R.P.D.</collab><article-title>RCSB PDB: Homepage</article-title><comment>20 September 2020, <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link></comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Biovia</surname><given-names>D. S.</given-names></name></person-group><source><italic toggle="yes">Discovery Studio 2020</italic></source><year>2020</year><publisher-name>San Diego Dassault Syst&#x000e8;mes</publisher-name></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O.</given-names></name><name><surname>Olson</surname><given-names>A. J.</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source><italic toggle="yes">Journal of Computational Chemistry</italic></source><year>2009</year><volume>31</volume><issue>2</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="other">2-s2.0-76149120388</pub-id><?supplied-pmid 19499576?><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Dallakyan</surname><given-names>S.</given-names></name></person-group><source><italic toggle="yes">MGLTools</italic></source><year>2010</year><comment>20 September 2020, <ext-link ext-link-type="uri" xlink:href="http://mgltools.scripps.edu/">http://mgltools.scripps.edu/</ext-link></comment></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>K.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-F.</given-names></name><name><surname>Lin</surname><given-names>S.-R.</given-names></name><name><surname>Yang</surname><given-names>J.-M.</given-names></name></person-group><article-title>iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2011</year><volume>12</volume><issue>S1</issue><fpage>p. S33</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-S1-S33</pub-id><pub-id pub-id-type="other">2-s2.0-79951520837</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Systemes</surname><given-names>D.</given-names></name></person-group><source><italic toggle="yes">BIOVIA Discovery Studio Visualizer 2016</italic></source><year>2016</year><publisher-name>San Diego CA Dassault Syst</publisher-name></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>DeLano</surname><given-names>W. L.</given-names></name></person-group><source><italic toggle="yes">The PyMOL molecular graphics system, Version 1.3 r1</italic></source><year>2010</year><publisher-name>Schr&#x000f6;dinger LLC N. Y</publisher-name></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>A. L.</given-names></name></person-group><source><italic toggle="yes">Statistical Methods for Evaluating Safety in Medical Product Development</italic></source><year>2015</year><publisher-name>John Wiley &#x00026; Sons</publisher-name></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties</article-title><source><italic toggle="yes">Journal of Chemical Information and Modeling</italic></source><year>2012</year><volume>52</volume><issue>11</issue><fpage>3099</fpage><lpage>3105</lpage><pub-id pub-id-type="doi">10.1021/ci300367a</pub-id><pub-id pub-id-type="other">2-s2.0-84870017710</pub-id><?supplied-pmid 23092397?><pub-id pub-id-type="pmid">23092397</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>V.</given-names></name><name><surname>Venkatesan</surname><given-names>B.</given-names></name><name><surname>Tumala</surname><given-names>A.</given-names></name><name><surname>Vellaichamy</surname><given-names>E.</given-names></name></person-group><article-title>Topical application of Gallic acid suppresses the 7,12-DMBA/croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice</article-title><source><italic toggle="yes">Food and Chemical Toxicology</italic></source><year>2014</year><volume>66</volume><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2014.01.017</pub-id><pub-id pub-id-type="other">2-s2.0-84893636614</pub-id><?supplied-pmid 24444547?><pub-id pub-id-type="pmid">24444547</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>S.</given-names></name><name><surname>Badana</surname><given-names>A. K.</given-names></name><name><surname>G</surname><given-names>M. M.</given-names></name><name><surname>G</surname><given-names>S.</given-names></name><name><surname>Malla</surname><given-names>R. R.</given-names></name></person-group><article-title>Reactive oxygen species: a key constituent in cancer survival</article-title><source><italic toggle="yes">Biomarker Insights</italic></source><year>2018</year><volume>13</volume><fpage>p. 117727191875539</fpage><pub-id pub-id-type="doi">10.1177/1177271918755391</pub-id><pub-id pub-id-type="other">2-s2.0-85052647368</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smina</surname><given-names>T. P.</given-names></name><name><surname>Nitha</surname><given-names>B.</given-names></name><name><surname>Devasagayam</surname><given-names>T. P. A.</given-names></name><name><surname>Janardhanan</surname><given-names>K. K.</given-names></name></person-group><article-title>
<italic>Ganoderma lucidum</italic> total triterpenes induce apoptosis in MCF-7 cells and attenuate DMBA induced mammary and skin carcinomas in experimental animals</article-title><source><italic toggle="yes">Mutation Research</italic></source><year>2017</year><volume>813</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2016.11.010</pub-id><pub-id pub-id-type="other">2-s2.0-85002810602</pub-id><?supplied-pmid 28010928?><pub-id pub-id-type="pmid">28010928</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakshmi</surname><given-names>B.</given-names></name><name><surname>Sheena</surname><given-names>N.</given-names></name><name><surname>Janardhanan</surname><given-names>K. K.</given-names></name></person-group><article-title>Prevention of mammary adenocarcinoma and skin tumour by <italic>Ganoderma lucidum</italic>, a medicinal mushroom occurring in South India</article-title><source><italic toggle="yes">Current Science</italic></source><year>2009</year><volume>97</volume><issue>11</issue><fpage>1658</fpage><lpage>1664</lpage></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>R. R. M.</given-names></name></person-group><article-title>Ganoderma - a therapeutic fungal biofactory</article-title><source><italic toggle="yes">Phytochemistry</italic></source><year>2006</year><volume>67</volume><issue>18</issue><fpage>1985</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2006.07.004</pub-id><pub-id pub-id-type="other">2-s2.0-33748091693</pub-id><?supplied-pmid 16905165?><pub-id pub-id-type="pmid">16905165</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Aggarwal</surname><given-names>B. B.</given-names></name><name><surname>Sung</surname><given-names>B.</given-names></name><name><surname>Gupta</surname><given-names>S. C.</given-names></name></person-group><source><italic toggle="yes">Inflammation and Cancer</italic></source><year>2014</year><publisher-name>Springer Basel</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-0348-0837-8</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colland</surname><given-names>F.</given-names></name><name><surname>Formstecher</surname><given-names>E.</given-names></name><name><surname>Jacq</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells</article-title><source><italic toggle="yes">Molecular Cancer Therapeutics</italic></source><year>2009</year><volume>8</volume><issue>8</issue><fpage>2286</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0097</pub-id><pub-id pub-id-type="other">2-s2.0-68849126660</pub-id><?supplied-pmid 19671755?><pub-id pub-id-type="pmid">19671755</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghajanian</surname><given-names>C.</given-names></name><name><surname>Soignet</surname><given-names>S.</given-names></name><name><surname>Dizon</surname><given-names>D. S.</given-names></name><etal/></person-group><article-title>A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies</article-title><source><italic toggle="yes">Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</italic></source><year>2002</year><volume>8</volume><issue>8</issue><fpage>2505</fpage><lpage>2511</lpage></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavabre-Bertrand</surname><given-names>T.</given-names></name><name><surname>Henry</surname><given-names>L.</given-names></name><name><surname>Carillo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies</article-title><source><italic toggle="yes">Cancer</italic></source><year>2001</year><volume>92</volume><issue>10</issue><fpage>2493</fpage><lpage>2500</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20011115)92:10&#x0003c;2493::AID-CNCR1599&#x0003e;3.0.CO;2-F</pub-id><?supplied-pmid 11745181?><pub-id pub-id-type="pmid">11745181</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filali</surname><given-names>H.</given-names></name><name><surname>Quessar</surname><given-names>A.</given-names></name><name><surname>Henry</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Quantification by ELISA of serum and intracellular 20S proteasome in a healthy Moroccan population</article-title><source><italic toggle="yes">International Journal of Innovation and Applied Studies</italic></source><year>2014</year><volume>7</volume><issue>2</issue><fpage>p. 522</fpage></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oerlemans</surname><given-names>R.</given-names></name><name><surname>Berkers</surname><given-names>C. R.</given-names></name><name><surname>Assaraf</surname><given-names>Y. G.</given-names></name><etal/></person-group><article-title>Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide</article-title><source><italic toggle="yes">Investigational New Drugs</italic></source><year>2018</year><volume>36</volume><issue>5</issue><fpage>797</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1007/s10637-018-0569-x</pub-id><pub-id pub-id-type="other">2-s2.0-85041905364</pub-id><?supplied-pmid 29442210?><pub-id pub-id-type="pmid">29442210</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K.</given-names></name></person-group><article-title>The proteasome: overview of structure and functions</article-title><source><italic toggle="yes">Proceedings of the Japan Academy. Series B, Physical and Biological Sciences</italic></source><year>2009</year><volume>85</volume><issue>1</issue><fpage>12</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2183/pjab.85.12</pub-id><pub-id pub-id-type="other">2-s2.0-59249084491</pub-id><?supplied-pmid 19145068?><pub-id pub-id-type="pmid">19145068</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahmi</surname><given-names>N.</given-names></name><name><surname>Anissi</surname><given-names>J.</given-names></name><name><surname>Jennan</surname><given-names>S.</given-names></name><name><surname>Farah</surname><given-names>A.</given-names></name><name><surname>Sendide</surname><given-names>K.</given-names></name><name><surname>Hassouni</surname><given-names>M. E.</given-names></name></person-group><article-title>Antioxidant activities and total phenol content of <italic>Inula viscosa</italic> extracts selected from three regions of Morocco</article-title><source><italic toggle="yes">Asian Pacific Journal of Tropical Biomedicine</italic></source><year>2015</year><volume>5</volume><issue>3</issue><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/S2221-1691(15)30010-1</pub-id><pub-id pub-id-type="other">2-s2.0-84922728849</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Ouariachi</surname><given-names>E.</given-names></name><name><surname>Bouyanzer</surname><given-names>A.</given-names></name></person-group><article-title>Antioxidant activity of solvent extracts of Inula viscosa from Morocco</article-title><source><italic toggle="yes">Arabian Journal of Chemical and Environmental Research</italic></source><year>2014</year><volume>1</volume><issue>1</issue><fpage>33</fpage><lpage>40</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B. W.</given-names></name><name><surname>Feeney</surname><given-names>P. J.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2001</year><volume>46</volume><issue>1&#x02013;3</issue><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id><pub-id pub-id-type="other">2-s2.0-0035289779</pub-id><?supplied-pmid 11259830?><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyay</surname><given-names>R. K.</given-names></name></person-group><article-title>Drug delivery systems, CNS protection, and the blood brain barrier</article-title><source><italic toggle="yes">BioMed Research International</italic></source><year>2014</year><volume>2014</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1155/2014/869269</pub-id><pub-id pub-id-type="other">2-s2.0-84911881604</pub-id><pub-id pub-id-type="publisher-id">869269</pub-id><?supplied-pmid 25136634?><pub-id pub-id-type="pmid">25136634</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Representative graphs of the effect of <italic>Inula viscosa</italic> L. extract on the evolution of skin carcinoma on Swiss albino mice.</p></caption><graphic xlink:href="BMRI2021-6687589.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The treatment with plant extract is applied only during the initiation phase. (a) Tumor multiplicity (average number of papillomas per mouse). (b) Tumor incidence (percentage of mice with papillomas).</p></caption><graphic xlink:href="BMRI2021-6687589.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The treatment with plant extract is applied only during the promotion phase. (a) Average number of papillomas per mouse. (b) Tumor incidence (percentage of mice with papillomas).</p></caption><graphic xlink:href="BMRI2021-6687589.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The treatment with plant extract is applied during the promotion and initiation phase. (a) Average number of papillomas per mouse. (b) Tumor incidence (percentage of mice with papillomas).</p></caption><graphic xlink:href="BMRI2021-6687589.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Hematoxylin and eosin staining of cross-sections of mouse skin and observed under light microscope. (a) Skin of control mice treated with the vehicle shows a normal distribution of the deferent skin layer. (b) Carcinogenesis group (DMBA/croton oil) showed epithelial vascular lesion, epidermal hyperplasia with hyperkeratosis, tumor nest, parakeratosis, spongiosis, and marked acanthosis. (c) Mouse skin treated with <italic>Inula viscosa</italic> extract showed normal skin structure and architecture with mild to moderate prevention of skin carcinogenesis.</p></caption><graphic xlink:href="BMRI2021-6687589.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Chymotrypsin-like catalytic activity in intracellular and serum levels. The difference is statistically significant (&#x02217;<italic>p</italic> &#x02264; 0.05; &#x02217;&#x02217;<italic>p</italic> &#x02264; 0.01; &#x02217;&#x02217;&#x02217;<italic>p</italic> &#x02264; 0.001).</p></caption><graphic xlink:href="BMRI2021-6687589.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Different types of interactions between tomentosin, inuviscolide, isocosticacid, and carfilzomib with 20S proteasome <italic>&#x003b2;</italic><sub>5</sub> subunit.</p></caption><graphic xlink:href="BMRI2021-6687589.007"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Screening results of 14 compounds extracted from <italic>Inula viscosa</italic> with 3D structures of proteasome <italic>&#x003b2;</italic><sub>1</sub>, <italic>&#x003b2;</italic><sub>2</sub>, and <italic>&#x003b2;</italic><sub>5</sub>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Compound name</th><th align="center" colspan="3" rowspan="1">Total binding energy<break/>(kcal&#x02009;mol<sup>&#x02212;1</sup>)</th><th align="center" rowspan="2" colspan="1">Structure</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>1</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>2</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>5</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tomentosin</td><td align="center" rowspan="1" colspan="1">-65.53</td><td align="center" rowspan="1" colspan="1">-62.63</td><td align="center" rowspan="1" colspan="1">-61.23</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2021-6687589.tab1.i001.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Inuviscolide</td><td align="center" rowspan="1" colspan="1">-64.53</td><td align="center" rowspan="1" colspan="1">-62.09</td><td align="center" rowspan="1" colspan="1">-62.41</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2021-6687589.tab1.i002.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Isocosticacid</td><td align="center" rowspan="1" colspan="1">-60.68</td><td align="center" rowspan="1" colspan="1">-57.9</td><td align="center" rowspan="1" colspan="1">-60.37</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2021-6687589.tab1.i003.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Carfilzomib</td><td align="center" rowspan="1" colspan="1">-86.07</td><td align="center" rowspan="1" colspan="1">-91.79</td><td align="center" rowspan="1" colspan="1">-99.58</td><td align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2021-6687589.tab1.i004.jpg"/>
</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Stowage results showing the best conformation, ranked according to their binding affinity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Compound name</th><th align="center" colspan="3" rowspan="1">Total binding energy<break/>(kcal&#x02009;mol<sup>&#x02212;1</sup>)</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>1</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>2</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
<sub>5</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tomentosin</td><td align="center" rowspan="1" colspan="1">-6.3</td><td align="center" rowspan="1" colspan="1">-6.5</td><td align="center" rowspan="1" colspan="1">-6.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Inuviscolide</td><td align="center" rowspan="1" colspan="1">-6.2</td><td align="center" rowspan="1" colspan="1">-6.4</td><td align="center" rowspan="1" colspan="1">-6.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Isocosticacid</td><td align="center" rowspan="1" colspan="1">-6.1</td><td align="center" rowspan="1" colspan="1">-6</td><td align="center" rowspan="1" colspan="1">-6</td></tr><tr><td align="left" rowspan="1" colspan="1">Carfilzomib</td><td align="center" rowspan="1" colspan="1">-5.1</td><td align="center" rowspan="1" colspan="1">-5</td><td align="center" rowspan="1" colspan="1">-5.2</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Interactions of the proposed compounds with the <italic>&#x003b2;</italic><sub>5</sub> receptor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Compounds</th><th align="center" rowspan="1" colspan="1">Residues</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tomentosin</td><td align="center" rowspan="1" colspan="1">Arg(70),Leu(66),Asn(63),Tyr(67),Phe(83),Leu(75),Val(64),Ala(79)</td></tr><tr><td align="left" rowspan="1" colspan="1">Inuviscolide</td><td align="center" rowspan="1" colspan="1">Glu(151),Asp(154),Leu(147),Leu(155),Gly(142),Arg(141),Val(138),Arg(154)</td></tr><tr><td align="left" rowspan="1" colspan="1">Isocosticacid</td><td align="center" rowspan="1" colspan="1">Glu(117),Asp(115),Tyr(113),Tyr(136),Ile(121),Phe(126),Val(128),Ser(127),Gly(129)</td></tr><tr><td align="left" rowspan="1" colspan="1">Carfilzomib</td><td align="center" rowspan="1" colspan="1">Gly(47),Gly(98),Ala(46),Val(128),Tyr(113),Ile(121),Phe(126),Ser(132),Ser(127,Gly(129),Tyr(136),Val(133)</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Molecular properties for predicting the drug sensitivity of 14 compounds extracted from <italic>Inula viscosa.</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Compound</th><th align="center" rowspan="1" colspan="1">MW</th><th align="center" rowspan="1" colspan="1">LogP</th><th align="center" rowspan="1" colspan="1">HB acceptor</th><th align="center" rowspan="1" colspan="1">HB donor</th><th align="center" rowspan="1" colspan="1">Rotating bonds</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Inuviscolide</td><td align="center" rowspan="1" colspan="1">248.32</td><td align="center" rowspan="1" colspan="1">2.2114</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Isocosticacid</td><td align="center" rowspan="1" colspan="1">234.33</td><td align="center" rowspan="1" colspan="1">3.934</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Tomentosin</td><td align="center" rowspan="1" colspan="1">248.32</td><td align="center" rowspan="1" colspan="1">2.8097</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Carfilzomib</td><td align="center" rowspan="1" colspan="1">719.91</td><td align="center" rowspan="1" colspan="1">2.5835</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">24</td></tr></tbody></table></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Pharmacokinetics and toxicity evaluation of compounds from <italic>Inula viscosa</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Inuviscolide</th><th align="center" rowspan="1" colspan="1">Isocosticacid</th><th align="center" rowspan="1" colspan="1">Tomentosin</th><th align="center" rowspan="1" colspan="1">Carfilzomib</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<italic>Absorption and distribution</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood-brain barrier (LogBB)</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">0.341</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">-1.082</td></tr><tr><td align="left" rowspan="1" colspan="1">Intestinal absorption (human)</td><td align="center" rowspan="1" colspan="1">97.306</td><td align="center" rowspan="1" colspan="1">93.881</td><td align="center" rowspan="1" colspan="1">97.922</td><td align="center" rowspan="1" colspan="1">55.371</td></tr><tr><td align="left" rowspan="1" colspan="1">Caco-2 permeability</td><td align="center" rowspan="1" colspan="1">1.288</td><td align="center" rowspan="1" colspan="1">1.593</td><td align="center" rowspan="1" colspan="1">1.343</td><td align="center" rowspan="1" colspan="1">0.056</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Metabolism</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Substrate CYP2D6</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Substrate CYP3A4</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhibitor CYP1A2</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhibitor CYP2C9</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhibitor CYP2D6</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhibitor CYP2C19</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Inhibitor CYP3A4</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="5" rowspan="1">
<italic>Excretion and toxicity</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Clearance</td><td align="center" rowspan="1" colspan="1">1.057</td><td align="center" rowspan="1" colspan="1">1.162</td><td align="center" rowspan="1" colspan="1">1.276</td><td align="center" rowspan="1" colspan="1">1.027</td></tr><tr><td align="left" rowspan="1" colspan="1">AMES toxicity</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Carcinogens</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap></floats-group></article>